Objective: We aim to summarize reliable evidences of evidence-based medicine for the treatment and prevention of the 2019 novel coronavirus (2019-nCoV) by analyzing all the published studies on the clinical characteristics of patients with 2019-nCoV. Methods: PubMed, Cochrane Library, Embase, and other databases were searched. Several studies on the clinical characteristics of 2019-nCoV infection were collected for Meta-analysis.
Introduction
Since December 2019, the epidemic of 2019 novel coronavirus (2019-nCoV) infectious pneumonia in Wuhan, China. The Chinese government and researchers have taken rapid measures to control the epidemic [1] . On January 30, 2020, WHO declared that the epidemic of 2019-nCoV was a public health emergency of international concern (PHEIC). At present, the number of patients with 2019-nCoV infection is still rising, and its harm to human beings has exceeded the outbreak of Severe Acute Respiratory Syndrome (SRAS) in China, 2002 [2] . The clinical characteristics and the case fatality rate after 2019-nCoV infection have always been concerned by people, and it is also the focus of medical workers' research at present. However, due to the different design of different clinical studies and insufficient sample size, the conclusions of the published studies were different. In order to acquire more accurate conclusions on the clinical characteristics and mortality of patients with 2019-nCoV infection, we searched the relevant literatures and carried out single arm Meta-analysis [3] . Our findings provide important guidance for current clinical work on the prevention and treatment of 2019-nCoV infection.
Material and Methods

Search strategy
Three popular medical databases including PubMed, Cochrane Library, and Embase databases were searched for related literatures, using the following keywords: "2019-nCoV", "Coronavirus", "COVID-19", "SARS-CoV-2" and "Wuhan Coronavirus". Articles reviewed were dated up to February 2020. In this Meta-analysis, there was no language restriction. Only available data from published articles were collected. Data from unpublished papers were not included.
2.2
The inclusive and exclusive criteria 2.2.1 Inclusive criteria: studies that include randomized controlled trials, non-randomized controlled trials, case-control studies, cohort studies, cross-sectional studies, and also case reports on the clinical characteristics of patients with 2019-nCoV infection. Clinical characteristics of patients with 2019-nCoV infection include fever, cough, muscle soreness or fatigue, acute respiratory distress syndrome (ARDS), abnormal chest computer tomography (CT) detection, patients in critical condition, as well as death due to 2019-nCoV infection.
2.2.2
Exclusive criteria: articles were published repeatedly; studies did not include the research indicators needed for Meta-analysis; research data were missing.
Data extraction and paper quality evaluation
First of all, we screened the literature according to the literature abstract, excluding the articles that obviously do not meet the inclusive criteria, and then read the full article for re-screening. If any disagreement on the choice of the literature exists, a third evaluator will join to make the decision. All included literature were evaluated using the Newcastle-Ottawa Scale (NOS) [4] . The highest quality of the literature was 9 stars and the lowest 0 stars.
Statistical analysis
The statistical software Stata version 12.0 was used to carry out the single arm Meta-analysis. Original data included in the literature were first transformed by double arcsine method to make them conform to normal distribution and then analyzed in Stata. The initial conclusion obtained by Meta-analysis was then restored using formula (P=(sin(tp/2)) 2 ) to reach final conclusion. In order to objectively evaluate the publication bias of the included literature, the Egger test with P < 0.05 as the existence of publication bias was performed, the values larger than which were considered as no publication bias.
Results
Literature inclusion
A total of 284 articles were retrieved, among which 39 papers were removed due to repeated retrieval, 212 papers were removed after reading abstracts, 23 were eliminated after reading the full text. At the end, a total of 10 articles [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] were included in this Meta-analysis, including data from 50466 patients. The specific operation flow is shown in Figure 1 . The characteristics of the literature are shown in Table 1 .
Meta-analysis results
Through Meta-analysis, we found that among all the clinical characteristics of patients with 2019-nCoV infection, the incidence of fever was 89.1% ( Figure 2 ), that of cough was 72.2% ( Figure 3 ), and that of muscle soreness or fatigue was 42.5% ( Figure 4 ). The incidence of ARDS was 14.8% ( Figure 5 ), correspondingly that of abnormal chest CT detection was 96.6% ( Figure 6 ), severe cases in all infected cases occupied a percentage of 18.1% ( Figure 7 ). The case fatality rate of patients with 2019-nCoV infection was 4.3% ( Figure 8 ). Detailed results of Meta-analysis are shown in Table 2 .
Publication bias detection
The results of Egger test in Table 3 . There was publication bias in the Meta-analysis of the ARDS group(P=0.008)..
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-coronavirus cluster. It causes the third kind of zoonotic coronavirus disease after Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS). Wei Ji et al. [15] found that 2019-nCoV seemed to be a recombinant virus between bat coronavirus and coronavirus of another unknown origin. Kangpeng Xiao et al. [16] confirmed that malayan pangolins were the most likely intermediate host of 2019-nCoV. The research of Domenico Benvenuto et al. [17] found that 2019-nCoV was only closely related to the coronavirus isolated from chrysanthemum-headed bat in 2015. Their research suggests that bats may be the reservoir host for 2019-nCoV. According to the research by Peng Zhou et al. [18] and Fan Wu et al. [19] , it was found that the sequence homology between 2019-nCoV and SARS-CoV was 79.5%. The homology between 2019-nCoV and bat coronavirus at the genetic level was 96%.
Therefore, very likely it can be confirmed that 2019-nCoV comes from bats.
According to the results of Meta-analysis, we find that the most common symptoms of patients with 2019-nCoV infection were fever and cough, and most of the patients had abnormal chest CT. Some patients with 2019-nCoV infection had muscle soreness or fatigue, ARDS, and other symptoms. Diarrhea, hemoptysis, headache, sore throat, shock, and other symptoms only occurred among a small number of patients. The proportion of severe cases in all infected cases was 18.1%, and the case fatality rate was 4.3%. At present, the Chinese government has announced that the case fatality rate of patients with 2019-nCoV infection in China is 3.36%, which is lower than that of another two widely contagious zoonotic coronavirus diseases, SARS and MERS. Infection mortality rates of SARS and MERS are 9.6% [20] and 35% [21] , respectively.
Gaohong Sheng et al. [22] have shown that viral infection could increase the risk of pulmonary fibrosis. Xie et al. [23] found that 45% of patients showed signs of pulmonary fibrosis within one month after being infected with SARS-CoV. Hui et al. [24] revealed that 36% and 30% of patients infected with SARS-CoV developed pulmonary Based on the mechanism of pulmonary fibrosis after virus infection, we can formulate corresponding prevention and treatment proposals. The first is the treatment of 2019-nCoV infection. At present, a variety of drugs have been found to inhibit 2019-nCoV. Michelle L. Holshue et al. [26] achieved remarkable results in the treatment of patients with 2019-nCoV infection with remdesivir. This drug is currently in clinical trials. Second, it is necessary to inhibit the inflammatory reaction and reduce the exudation. On this direction, antibiotics not only have traditional antibacterial effects, but also have immunomodulatory and anti-inflammatory properties [27] . Macrolide antibiotics such as clarithromycin, azithromycin, and erythromycin prevent the production of pro-inflammatory cytokines and immune mediators [28] . The third is to inhibit the fibrogenic effect of TGF-β. Luo et al. [29] found that arsenic trioxide could inhibit the signal transduction of TGF-β and play a role in anti-fibrosis. The fourth is the rational use of ventilator to avoid unnecessary lung damages. In addition, pirfenidone and nintedanib as drugs for the treatment of idiopathic pulmonary fibrosis can also be used to prevent and treat pulmonary fibrosis in patients with 2019-nCoV infection [30] .
In all, a total of 10 articles were covered in the Meta-analysis, including 50466 patients with 2019-nCoV infection.
By far, it is the first Meta-analysis with the largest sample size. The quality of the literature included in this study is high, the analysis is rigorous, and the conclusions drawn by the study are highly credible. However, this
Meta-analysis also has some limitations: 1) All studies included in this Meta-analysis are retrospective studies with large heterogeneity; 2) Most patients in our Meta-analysis are Chinese, and we aimed to use the conclusions of this study to predict patients in general, including other countries and races; 3) There was publication bias in the Meta-analysis of the ARDS group. The analytical conclusion of the ARDS group may be influenced by publication bias. Therefore, based on the above limitations, the conclusions of this Meta-analysis still need to be verified by more relevant studies with more careful design, more rigorous execution, and larger sample size. 
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